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Abstract
Introduction: Of the nearly 1.4 million new cases of breast cancer diagnosed each year, a large proportion is
characterized as hormone receptor negative, lacking estrogen receptors (ER) and/or progesterone receptors (PR).
Patients with receptor-negative tumors do not respond to current steroid hormone-based therapies and generally
have significantly higher risk of recurrence and mortality compared with patients with tumors that are ER- and/or
PR-positive. Previous in vitro studies had shown that the progesterone metabolites, 5a-dihydroprogesterone (5aP)
and 3a-dihydroprogesterone (3aHP), respectively, exhibit procancer and anticancer effects on receptor-negative
human breast cell lines. Here in vivo studies were conducted to investigate the ability of 5aP and 3aHP to control
initiation, growth, and regression of ER/PR-negative human breast cell tumors.
Methods: ER/PR-negative human breast cells (MDA-MB-231) were implanted into mammary fat pads of
immunosuppressed mice, and the effects of 5aP and 3aHP treatments on tumor initiation, growth, suppression/
regression, and histopathology were assessed in five separate experiments. Specific radioimmunoassays and gas
chromatography-mass spectrometry were used to measure 5aP, 3aHP, and progesterone in mouse serum and
tumors.
Results: Onset and growth of ER/PR-negative human breast cell tumors were significantly stimulated by 5aP and
inhibited by 3aHP. When both hormones were applied simultaneously, the stimulatory effects of 5aP were
abrogated by the inhibitory effects of 3aHP and vice versa. Treatment with 3aHP subsequent to 5aP-induced
tumor initiation resulted in suppression of further tumorigenesis and regression of existing tumors. The levels of
5aP in tumors, regardless of treatment, were about 10-fold higher than the levels of 3aHP, and the 5aP:3aHP
ratios were about fivefold higher than in serum, indicating significant changes in endogenous synthesis of these
hormones in tumorous breast tissues.
Conclusions: The studies showed that estrogen/progesterone-insensitive breast tumors are sensitive to, and
controlled by, the progesterone metabolites 5aP and 3aHP. Tumorigenesis of ER/PR-negative breast cells is
significantly enhanced by 5aP and suppressed by 3aHP, the outcome depending on the relative concentrations of
these two hormones in the microenvironment in the breast regions. The findings show that the production of 5aP
greatly exceeds that of 3aHP in ER/PR-negative tumors and that treatment with 3aHP can effectively block
tumorigenesis and cause existing tumors to regress. The results provide the first hormonal theory to explain
tumorigenesis of ER/PR-negative breast tissues and support the hypothesis that a high 3aHP-to-5aP concentration
ratio in the microenvironment may foster normalcy in noncancerous breast regions. The findings suggest new
diagnostics based on the relative levels of these hormones and new approaches to prevention and treatment of
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breast cancers based on regulating the levels and action mechanisms of anti- and pro-cancer progesterone
metabolites.
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Introduction
Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death in women world-
wide, with nearly 1.4 million new cases annually [1].
Progesterone and estrogens have long been linked to
breast cancer [2,3], and current understanding of the
effective actions of these hormones implies the presence
of receptors (ER and PR) in the target cells [4,5]. How-
ever, a large proportion (about 30% to 60%) of breast
tumors are ER and/or PR negative [4,6-8], and about
90% of normal proliferating breast epithelial cells are
receptor negative [9]. Patients with receptor-negative
tumors generally show lack of response to adjuvant hor-
mone therapy and have significantly higher risk of mor-
tality compared with patients with tumors that are ER
and/or PR positive [10-14]. Overall, this means that for
receptor-negative breast cancers, current explanations
based on estrogen and progesterone actions and recep-
tors are inadequate, and the related hormone-based
therapies are ineffective. Here evidence is presented that
the progesterone metabolites, 5a-pregnane-3,20-dione
(5a-dihydroprogesterone; 5aP) and 4-pregnen-3a-ol-20-
one (3a-dihydroprogesterone; 3aHP), can regulate ER/
PR-negative breast cell tumor formation and growth as
well as tumor regression and maintenance of normalcy.
Our previous in vitro studies had shown that breast
tissues and cell lines readily convert progesterone to 5a-
pregnanes, such as 5aP, and delta-4-pregnenes, such as
3aHP (Figure 1), and that tumorous breast tissues [15]
and tumorigenic breast cell lines [16] produce higher
levels of 5aP and lower levels of 3aHP than do normal
breast tissues and nontumorigenic cell lines. The differ-
ences in progesterone metabolism between normal and
tumorous breasts were observed in all breast tissue sam-
ples examined, regardless of the ages of the women,
subtypes and grades of carcinomas, and whether the tis-
sues were ER and PR positive and/or negative [15]. The
progesterone metabolism studies suggested that
increases in 5aP and decreases in 3aHP production
accompany the shift toward breast cell neoplasia and
tumorigenicity [17]. In vitro studies on five different
human breast cell lines showed that cell proliferation
and detachment are significantly increased by 5aP and
decreased by 3aHP [15,18]. The opposing in vitro effects
of 5aP and 3aHP were observed in all breast cells stu-
died: tumorigenic and nontumorigenic, estrogen-respon-
sive and unresponsive, and ER/PR-positive and -negative
cells [18].
The objectives of the current studies were (a) to deter-
mine whether the progesterone metabolites, 5aP and
3aHP, have the ability to regulate in vivo induction and
growth of ER/PR-negative human breast cancer cell
tumors in mice, and (b) to determine the relative con-
centrations of 5aP and 3aHP in serum of tumorous and
nontumorous mice and within tumors. The studies pro-
vide the first in vivo evidence that initiation and growth
of ER/PR-negative human breast cell tumors are mark-















Figure 1 Conversion of progesterone to 3a-dihydroprogesterone (3aHP) and 5a-dihydroprogesterone (5aP). In vitro studies have shown
that both ER/PR-positive and -negative human breast tissues and cell lines are able to convert progesterone to 3aHP and 5aP by the actions of
3a-hydroxysteroid oxidoreductase (3a-HSO) and 5a-reductase, respectively.
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that established 5aP-induced tumors can be regressed
by treatment with 3aHP. Measurements of their levels
indicate that the relative concentrations in the breast
microenvironment of the progesterone metabolites
determine whether ER/PR-negative cells are stimulated
toward neoplasia and tumorigenesis or regulated to
maintain a normal state.
Methods and materials
Chemicals and reagents
Progesterone, 5aP, cell-culture media, insulin, penicillin,
and streptomycin were obtained from Sigma Chemical Co.
(Oakville, ON, Canada). 3aHP was obtained from Stera-
loids (Newport, RI, USA). Serum was purchased from
Invitrogen (Burlington, ON, Canada). [1,2,6,7-3H]Proges-
terone and [9,11,12-3H]5a-pregnan-3a-ol-20-one were
purchased from Perkin-Elmer (Woodbridge, ON, Canada).
Other chemicals and solvents were of appropriate analytic
grade and were purchased from Sigma Chemical Co.,
BDH Inc., (Toronto, ON, Canada), VWR (Mississauga,
ON, Canada), or Fisher Scientific Ltd. (Toronto, ON,
Canada). Ethanol was double (glass) distilled.
Cells
The human breast cell line MDA-MB-231 was obtained
from American Type Culture Collection (ATCC, Mana-
ssas, VA, USA), and cells were grown in a 1:1 Ham F12
Medium and Dulbecco Modified Eagle Medium with sup-
plements and 10% calf serum as described [18]. Cells were
grown in T-75 flasks (Sarstedt) and were harvested at
approximately 80% confluence. Cell-proliferation and
-detachment responses to 5aP and 3aHP were tested [15]
before harvesting for inoculation into animals, and cell via-
bility was determined with the trypan blue exclusion test.
Cells intended for inoculation into mice were harvested,
washed, and then suspended in serum-free medium
(about 5 × 106 cells per 100 μl).
Animals
Severe combined immunodeficiency (SCID) female mice
with impaired T- and B-cell lymphocyte development
(NOD SCID) were obtained from Charles River Labora-
tories (Saint-Constant, Quebec, Canada) at 5 to 6 weeks of
age and maintained under specific pathogen-free condi-
tions with food and water ad libitum. All animal handling
and procedures were approved by Western University
Institutional Care and Use Committee. After acclimation
(8 to 27 days), cells were implanted on day 0. Each mouse
was anesthetized with a mixture of isofluorane and oxy-
gen, and about 5 × 106 cells, suspended in 100 μl cold
(0°C to 4°C) serum-free medium, were injected into the
right thoracic mammary fat pad through a 5-mm incision
at the sternum region, by using a 1.0-ml syringe with 26-
gauge needle. The wound was closed in one layer with
metal wound clips or with tissue adhesive (3M Vetbond;
St. Paul, MN, USA). The surgical, injection, and handling
procedures were conducted in approved laminar-flow
sterility hoods. At termination (asphyxiation by CO2),
blood was collected, tumors were excised and weighed,
necropsies were conducted, and tissues were fixed in 10%
formalin for histopathologic observation (5-μm sections,
hematoxylin and eosin). Some tumors were stored in
methanol for steroid extraction.
Treatments
Suspensions of 5aP and 3aHP were prepared under ster-
ile conditions in sterile-filtered vehicle (0.9% NaCl in
double-distilled H2O, containing 0.1% double-distilled
ethanol and 0.05% Tween 80) at 4 to 5 mg/150 μl. The
suspensions were stored at 4°C before use and were
administered SC (150 μl/injection) by using a 1.0-ml syr-
inge with a 23-gauge needle in the nape of the neck.
Tumor growth monitoring
The growth of tumors was monitored at regular intervals
(weekly at first, and after appearance of palpable tumors,
every second day or every day). Tumor volumes were
determined from digital caliper measurements of length
and width. The formula (length × (width)2 × 0.6) was
determined to be a good approximation of tumor volumes
(mm3) as calculated empirically by water-displacement
measurements of various irregular tumorlike shapes and
sizes of modeling clay.
Synthesis of [3H]-5aP and 5aP-BSA conjugate
[9,11,12-3H]5aP was prepared by oxidation of [9,11,12-3H]
5a-pregnan-3a-ol-20-one, as described [19]. Purification
of [3H]-labeled 5aP was by high-pressure liquid chromato-
graphy (HPLC; C18 column and methanol/water, 3:1) and
TLC (Fisherbrand silica gel GF; three runs in hexane:ethyl
acetate, 5:2) [19,20]. Preparation of 5a-pregnane-3,20-
dione-11a-hemisuccinate-BSA (5aP-BSA conjugate) was
by previously described procedures [21,22], and purity of
the conjugate was confirmed with HPLC in the solvent
system acetonitrile:H2O:trifluoroacetic acid (45:55:0.1) by
using a Vydac C4 column (4.6 × 250 mm) for protein with
particle size, 5 μm, and pore diameter, 300 A.
Synthesis of [3H]3aHP
Tritiated 3aHP ([1,2,6,7-3H]3aHP) was prepared from
freshly TLC-cleaned [1,2,6,7-3H]progesterone by using
potassium trisamylborohydride (KS-Selectride; Aldrich) as
reducing agent, as described [20,23], with some modifica-
tions. In brief, [3H]progesterone (50 to 100 μCi) was trans-
ferred to a dry siliconized reaction tube; the ethanol was
evaporated under N2, and the tube was dried overnight in
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a vacuum desiccator over gypsum (Drierite). Dry molecu-
lar sieves (3 to 4) were added to the tube under an N2
cone, and the tube was sealed with a rubber septum. Dry
tetrahydrofuran (THF; 200 μl) was added, and the
N2-purged tube was cooled to -80°C. The reaction was
initiated at -80°C with slow dropwise addition of cold KS-
Selectride (100 μl) under an N2-purged atmosphere and
with gentle agitation. After 1 hour, the reaction was con-
tinued in an ice bath (0°C) for another 3 hours and termi-
nated with the addition of 1.0 ml THF and 1.5 ml cold (0°
C) 0.1N NaOH. The reaction mixture was extracted 3
times with 5 ml ethyl ether or ether:CH2Cl2 (5:1) and
cleaned by backwashing and C18 bonded silica gel col-
umns. The reaction products were separated and purified
with TLC and HPLC, as described earlier under Synthesis
of [3H]-5aP, and [3H]3aHP was stored in double-distilled
ethanol (purged under N2), at -20°C.
Preparation of antisera
The 3aHP antiserum (lyophilized) was from our stock
originally generated in rabbits by using a 3aHP-carboxy-
methyloxime-BSA conjugate [20]. For the preparation of
5aP and progesterone antiserum, two male SPF New
Zealand white rabbits were immunized with 5aP-BSA,
and titer was determined. The serum was stored at -80°C.
The antiserum from Rabbit 1 showed high specificity for
5aP, and low cross reaction (percentage relative to 5aP
at 100%) with progesterone (2.2%), 3aHP (1.3%), estra-
diol (2.2%), 4-pregnen-20a-ol-3-one (0.9%), and other
5a-pregnanes and testosterone (<0.1%). The serum from
Rabbit 2 had lower specificity for 5aP but acceptable spe-
cificity for progesterone and was therefore used for the
progesterone radioimmunoassay (RIA).
Steroid extractions from serum and tumor tissues
Sera (100 to 300 μl) from 29 mice from different experi-
ments were extracted 3 times with 2.0 ml ether/chloroform
(6:1). The water and organic solvent phases were separated
by freezing (-80°C), the combined solvent portions were
dried down under a stream of N2, and the residue was
brought up in 0.5 ml of methanol/CH2Cl2 (5:1), purged
with N2, and stored at -20°C until chromatography was
performed. Tumors were weighed, cut into pieces, and
homogenized in 5-ml methanol by using a Polytron and
extracted with methanol and 3 times with ether/CH2Cl2
(5:1). The combined solvent was evaporated under N2, and
the samples brought up in methanol/CH2Cl2 (5:1) were
cleaned by solid-phase extraction (C18-bonded silica gel
columns) [20] by using methanol/CH2Cl2 (20:1) as eluant
at a flow rate of about 0.8 ml/min. The fractions containing
the steroids were combined, evaporated under N2, and
brought up in 0.5 ml methanol/CH2Cl2 (5:1), purged with
N2, and stored at -20°C until chromatography.
Chromatographic separation of progesterone, 5aP, and
3aHP
Thin-layer chromatography (TLC) of serum and tumor
extracts was performed on 20 × 20-cm silica gel G(F)
TLC plates (250 μm; Fisher Scientific, Pittsburgh, PA,
USA). Extracts and standards (5aP, 3aHP, progesterone)
were run in separate lanes (2×) in a solvent system con-
sisting of hexane/chloroform/ethyl acetate (60:60:30).
The standards were located by UV absorption and expo-
sure to iodine vapors and, on average, were located at Rf
of 0.62 (5aP), 0.44 (progesterone), and 0.27 (3aHP).
Regions in the sample lanes coinciding with the stan-
dards were extracted with ether/chloroform (6:1); the
extracts were evaporated under N2 and brought up in
0.4-ml double-distilled ethanol.
Radioimmunoassays
The RIAs for 5aP, 3aHP, and progesterone were basi-
cally as described [20], with the generated antisera (see
earlier) and scintillation spectrometry (Beckman-Coulter
LS 6500 Scintillation Counter). For purposes of compar-
ison, concentrations were standardized to nanograms
per milliliter for serum and nanograms per gram for
tumors, and it was assumed that these two measures
represent a reasonable equivalence.
Mass spectrometry
For verification of RIA measurements of 5aP, 3aHP, and
progesterone, portions of TLC-separated extracts from
four tumor tissues were tested with both RIA and GC/
MS (Hewlett-Packard GC-Mass Spectrometer, model
5790A/5970A, used in the selected ion mode (SIM) with
a DB-1MS 12-m × 0.2 mm × 0.33 μm cross-linked
methyl silicone capillary column). The conditions were
similar to those described previously [20]: splitless mode,
0.7 kg/cm2 helium, 230°C injection temperature, column
temperature at 150°C (initial) to 230°C at 20°/min, and
scan speed of 690 amu/sec at an electron multiplier set-
ting of 2,200 V. Underivatized authentic standards at var-
ious concentrations as well as samples were brought up
in 10 μl MeOH or CH2Cl2, and 5 μl was injected for each
GC/MS analysis. The authentic steroids were first run in
standard mode, which showed that, under the condition
employed, 5aP and progesterone each eluted as single
peaks (at about 12.5 and 14.2 minutes, respectively), and
3aHP eluted as three separate peaks consisting of two
isomeric dehydrated moieties and whole 3aHP (at 7.6,
8.3, and 11.1 minutes, respectively) (see Additional file
1A). The runs in standard mode also showed that the
major ions (m/e) were 246, 283, 298, and 316, for 3aHP
and its two dehydrated fragments; 231, 258, 298, and 316
for 5aP; and 124, 229, 272, and 314 for progesterone
(Additional file 1B through E). Authentic steroids and
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sample extracts were then run in SIM set for the respec-
tive major ions. Quantification of samples was calculated
by comparison with concentration curves developed
from standards (range of 0.04 to 20 ng), and the limit of
detection was about 50 pg.
Statistical analyses
Statistical analyses were carried out with GraphPad
Instat software (Graph-Pad Software, Inc., San Diego,
CA, USA). Results are presented as mean ± SEM and
were analyzed with the unpaired Student t test, with P <
0.05 considered statistically significant.
Results
The human breast cell line MDA-MB-231 was chosen
because these ER/PR-negative cells have been shown to
exhibit opposing responses to 5aP and 3aHP in vitro
[18], and because they have the capacity to form tumors
spontaneously (without estrogen or progesterone sup-
plements) when implanted into the mammary fat pad of
immunodeficient mice [24]. The latter feature was con-
sidered important to study the potential of both stimula-
tion and suppression of tumorigenesis. In vitro tests
confirmed that proliferation of the passages of MDA-
MB-231 cells used in the animal trials was significantly
stimulated by 5aP and suppressed by 3aHP (Figure 2).
ER/PR-negative breast cell tumorigenesis and tumor
growth are stimulated by 5aP and suppressed by 3aHP
To test the potential of 5aP to stimulate ER/PR-negative
breast tumor formation and growth, 11 mice, 6 weeks
old, were divided into two groups, five controls and six
treated (Figure 3A). Three days (day -3) before cell
implantation, they received a single injection of either
vehicle (controls) or vehicle containing 5aP (Figure 3A,
inset). The day of cell inoculation was considered as day
0, and the trial was terminated on day 40. In three of
five controls and in six of six 5aP-treated mice, tumors
developed. In the controls, small palpable tumors were
first detected in two mice on day 28 and in the third
mouse on day 32. Of the 5aP-treated mice, two had
palpable tumors on day 21, and all six, by day 27. The
tumors in the six 5aP-treated mice grew more rapidly
and were on average 4.2-fold larger at termination than
the three tumors in the control mice (P < 0.05). The
results showed that incidence, onset, and growth of ER/
PR-negative human breast cell tumors are stimulated by
the progesterone metabolite, 5aP.
To determine whether 5aP and 3aHP have opposing
actions on ER/PR-negative breast cell tumor formation,
24 mice were divided into four groups of six mice each
and injected twice (on day -2 and day 12) with vehicle
(control), or vehicle containing either 5aP, 3aHP, or
5aP+3aHP (Figure 3B). In the control group, a palpable
tumor was observed in one mouse on day 33 and in four
others by day 39, and the tumor size (mean ± SEM) was
164.4 ± 40.2 mm3 on day 46 and 409.8 ± 73.8 mm3 at ter-
mination (day 59). In the 5aP-treated group, two mice
had palpable tumors by day 20, four by day 23, and all six
by day 33; the tumors developed very rapidly, so that by
day 46, the tumor volume was 2,431.8 ± 374.4 mm3 (14.8-
fold larger than in the controls; P < 0.001), and the tumor
burden required termination of this group. In the 3aHP-
treated group, palpable tumors were detected in two mice
on day 37 and in two other mice by day 41, with average
size of 69.2 ± 6.6 mm3 on day 46, and 159.6 ± 32.1 mm3
on day 59, significantly smaller (P < 0.05) than those in
the controls. In the group treated with 3aHP+5aP, palp-
able tumors were detected in two mice on day 35 and in
three more on day 39, with average size of 351.6 ± 43.3
mm3 on day 46, and 1,020 ± 140 mm3 on day 59. In com-
parison with the 5aP-only treated group, the results of the
combined treatment (3aHP+5aP) showed that 3aHP sig-
nificantly suppressed the 5aP-induced onset and growth
of tumors (P < 0.001); tumor volume was 11.3-fold smaller
than in the 5aP-only group on day 46. Conversely, 5aP
significantly countered the suppressive action of 3aHP in






















Figure 2 Opposing in vitro effects of 5aP and 3aHP on
proliferation of MDA-MB-231 cells used in the in vivo
(xenograft) studies. Cells were seeded at 4 × 104 cells per dish,
allowed to attach for 24 hours, and then treated for 72 hours
without (C, control) or with 10-6 M 5aP and/or 3aHP, and
proliferation was determined by cell counts. Data are presented as
cell number (mean and SEM; n = 4). **P < 0.01, ***P < 0.001 for the
indicated comparisons or versus the control.
Wiebe et al. Breast Cancer Research 2013, 15:R38
http://breast-cancer-research.com/content/15/3/R38










































































20 25 30 35 4015
-1 0-2-3 1 2day
treatment
cells implanted
Figure 3 ER/PR-negative breast cell tumor induction and growth are regulated by 5aP and 3aHP. (A) Tumor induction and growth are
stimulated by 5aP. MDA-MB-231 cells were implanted in mammary fat pads of 11 mice (day 0, inset); 3 days before (day -3), five mice were
injected with vehicle (control; black open circles), and six were injected with 5aP (red, solid circles). Data points represent size (mm3; mean ±
SEM) of tumors that developed of a total number of mice per treatment (bracketed values), and the experiment was terminated on day 40.
*Significantly different from controls at P < 0.05. (B) Tumor induction and growth are stimulated by 5aP and inhibited by 3aHP. Twenty-four
mice were divided into four groups of six mice each, and MDA-MB-231 cells were implanted on day 0 (inset). Two days before (day -2) and on
day 12, mice were injected with either vehicle (control; black open circles), 5aP (red, solid circles), 3aHP (blue inverted triangles), or 5aP+3aHP
(green squares). The 5aP-treated mice were terminated on day 46 because of tumor burden, and the other mice were terminated on day 59.
Data points represent size (mm3; mean ± SEM) of tumors that developed of a total number of mice per treatment (bracketed values).
Significantly different from controls at *P < 0.05 and ***P < 0.001.
Wiebe et al. Breast Cancer Research 2013, 15:R38
http://breast-cancer-research.com/content/15/3/R38
Page 6 of 15
combined-treatment group was 4.7-fold larger than that in
the 3aHP-only treated group on day 59. The experiment
was repeated (see Additional file 3), and the overall results
confirmed that 5aP treatment stimulated, whereas 3aHP
inhibited, tumor initiation and growth, whereas simulta-
neous treatment with both hormones (3aHP+5aP) resulted
in abrogation of the effects of either hormone alone.
3aHP results in suppression and regression of 5aP-
stimulated ER/PR-negative breast tumors
These experiments showed that the stimulatory effects of
5aP and the inhibitory effects of 3aHP are abrogated
when the two hormones are given simultaneously, starting
near the time of cell implantation. Two experiments were
conducted to determine whether 3aHP can suppress and/
or reverse the tumorigenic effects initiated by prior treat-
ments with 5aP. The first experiment (Figure 4A) was
conducted to determine if multiple treatments with 3aHP
over an extended period result in a higher level/incidence
of suppression of tumorigenesis. Fourteen mice were trea-
ted with 5aP on day -3 and day 11, and then seven of
these mice continued to be treated with 5aP (Group I),
whereas the other seven (Group II) were treated with
3aHP on days 27, 36, and 47 (Figure 4A, inset). Two mice
were excluded from the final analysis: one from Group I,
which failed to develop a tumor, and one from Group II,
which started to develop an aggressive tumor just 9 days
after the first treatment with 3aHP (about 5 to 6 weeks
before the onset of any other tumor). At termination (day
96), all (six of six) of Group I mice had tumors (1,034.4 ±
399.1 mm3), and none (none of six) of Group II mice had
tumors, indicating more-marked suppression of 5aP-sti-
mulated tumorigenesis by multiple 3aHP treatments.
The second experiment (Figure 4B) was conducted to
determine whether 3aHP can reverse the tumorigenic
effects initiated by prior treatments with 5aP. Twenty-
four mice received three subcutaneous injections (days 0,
20, and 61) of 5aP. Then, on day 75, 14 mice with simi-
lar-sized small palpable tumors (18 to 34 mm3) were
divided into two groups, consisting of seven mice each,
which received one injection of either vehicle (control) or
3aHP (Figure 4B, inset). At termination 24 days later, all
seven of the control mice had enlarged tumors (950.9 ±
277.6 mm3), whereas of the seven 3aHP-treated mice,
four had regressed to either no palpable tumors or just
tiny nodules (≤5 mm3), and three had relatively small
tumors (333.7 ± 90.1 mm3), indicating marked suppres-
sion and regression of 5aP-induced tumors by treatment
with 3aHP.
Effect of treatments on health and condition of animals
and on tumor histopathology
At termination of experiments, mice from all treatment
groups appeared to be in good body condition; no
significant differences were noted in body-weight gain
and in general appearance and condition of liver, lung,
kidney, heart, and adrenals between control mice and
mice from different treatments. Mice with enlarged
tumors were observed to have some enlargement of the
pancreas and spleen. The large 5aP-stimulated tumors
tended to extend from the right ventral mammary fat
pad area and laterally to the dorsal thoracic area near the
steroid depots (Figure 5A). Histopathologic analyses of
tumors from 5aP-treated mice showed hypercellular
solid carcinomas invading the muscle and other outer
aspects of the thoracic cavity (Figure 5B) and exhibited
frequent mitoses (Figure 5C). In contrast, residual tumors
in 3aHP-treated mice (Figure 5D) showed little or no
invasion into surrounding tissue (Figure 5E) and gener-
ally exhibited less-frequent mitoses and more-frequent
multifocal necroses (Figure 5F).
Concentrations of 5aP and 3aHP in serum and tumors
Validation of RIA measurements by mass spectrometry
To determine the levels of 5aP, 3aHP, and progesterone
in serum and tumors, RIAs specific for these steroids were
used. For validation of the RIA measurements, aliquots of
TLC-separated 5aP, 3aHP, and progesterone extracts
from four tumors were tested with both RIA and gas chro-
matography-mass spectrometry (GC-MS). The results
showed no significant differences between RIA and
GC-MS measurements of hormone levels (see Additional
file 2) and provided validation of the reliability of the RIA
measurements.
Serum levels of 3aHP and 5aP are elevated after hormone
treatments
To determine whether steroid treatments resulted in
increased concentrations in the circulation, serum sam-
ples from vehicle (control) and hormone-injected mice
were analyzed for 5aP and 3aHP at 15 to 22 days and 42
days after the last treatment (Figure 6A). Although 5aP
and 3aHP concentrations were about the same (2 to 3
ng/ml) at both time periods in the vehicle-injected mice,
the concentrations were significantly higher (about three-
fold to sixfold) in treated mice at 15 to 22 days after
hormone injections and had declined to control levels by
42 days.
Levels of 5aP are higher in serum from control mice with
tumors than in those without tumors
Measurements of hormone levels in serum of control ani-
mals (vehicle only) at termination showed that the 5aP
concentrations were significantly higher (P < 0.05) in mice
with tumors than in mice without tumors (Figure 6B).
Also, in serum from control mice with tumors, the con-
centrations of 5aP were significantly higher (P < 0.01)
than the concentrations of 3aHP, resulting in significantly
higher 5aP/3aHP ratios (P < 0.01) than in serum from
mice without tumors (Figure 6C).
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Tumors have higher levels of 5aP than 3aHP and higher
5aP/3aHP concentration ratios than serum
To determine whether levels of 5aP and 3aHP in
tumors are affected by hormone treatments, tumors
from mice that had received vehicle, 5aP, or 3aHP
injections before tumor initiation were analyzed at ter-
mination (Figure 7A). The results showed no significant
differences in tumor hormone levels due to treatments.
All the tumors had significantly higher levels of 5aP
(about 10-fold) than 3aHP (P < 0.01), and the 5aP/
3aHP ratios were not significantly different between
tumors from mice with different treatments (Figure 7B).
To compare hormone concentrations in tumors and
respective sera, levels of 5aP, 3aHP, and progesterone
were determined in samples from nine tumorous mice
(Figure 7C). The levels of 5aP were significantly higher
(P < 0.01), and those of 3aHP were significantly lower
(P < 0.01) in tumors than in serum, whereas the
progesterone levels did not differ significantly. In
tumors, the concentrations of 5aP were on average
more than 10-fold higher than those of 3aHP, and the
5aP/3aHP ratios were more than fivefold greater than
in the respective sera (Figure 7D; P < 0.001). Signifi-
cantly higher levels of 5aP than of 3aHP were also con-
firmed in samples from the four tumors analyzed with
mass spectrometry (Additional file 2).
Discussion
“receptor-negative” breast cancers fail to benefit from cur-
rent hormonal therapies, but they also generally exhibit
more-aggressive biologic behaviors and poorer prognosis
than the receptor-positive ones [10-14]. The results of the
studies reported here show for the first time that the pro-
gesterone metabolites, 5aP and 3aHP, act as hormones
that regulate ER/PR-negative breast tumor formation,





















































Figure 4 3aHP results in suppression and regression of 5aP-induced ER/PR-negative tumors. (A) 3aHP suppresses ER/PR-negative breast
cell tumorigenesis in 5aP-pretreated mice. Fourteen mice were treated with 5aP on day -3 and day 11 and then were divided into two groups.
One group (Group I) continued to be treated with 5aP, whereas the other group (Group II) was treated with 3aHP on days 27, 36, and 47
(Inset). One mouse from each group was excluded from the final analysis, as explained under Results. The data are presented as the percentage
of mice with tumors at termination. (B) 3aHP results in regression of 5aP-induced ER/PR-negative breast cell tumors. Twenty-four mice with
MDA-MB-231 cell implants received injections of 5aP on days 0, 20, and 61 (inset); on day 75, the 14 mice with approximately similar-sized small
palpable tumors (18 to 34 mm3) were divided into two groups, consisting of seven mice each, which received a single injection of either vehicle
(veh) or 3aHP, and the experiment was terminated 24 days later. Bars represent size (mm3; mean ± SEM) of tumors that developed of a total
number of mice per treatment (bracketed values), at the start of treatments (day 75, Initial) and at termination (day 99, Final).
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human breast cell tumors in mice was considerably accel-
erated, and the growth significantly stimulated, by just one
or two applications of 5aP. In contrast, 3aHP retarded
onset of tumor formation, suppressed tumor growth, and
inhibited or regressed existing 5aP-induced tumors.
When both hormones were administered simultaneously,
the effects of one were abrogated by the effects of the
other. The current in vivo demonstrations, from five sepa-
rate experiments, of the opposing actions of 5aP and
3aHP on tumorigenesis and tumor growth extend the
previous findings, which showed opposing in vitro cancer-
regulatory actions of these progesterone metabolites on
receptor-negative (MDA-MB-231, MCF-10A) as well as
receptor-positive (MCF-7, T47D, ZR-75-1) breast cell lines
[15,17,18].
The response of ER/PR-negative breast cells to the
progesterone metabolites can be explained by the pre-
sence of specific high-affinity receptors for 5aP (5aPR)
and 3aHP (3aHPR). The 5aPR and 3aHPR (which are
associated with the plasma membranes of both ER/PR-
positive [19] and ER/PR-negative [29] cells) are distinct
from each other and from known ER, PR, androgen, and
corticosteroid receptors, and lack affinity for other ster-
oids, such as progesterone, estrogen, androgens, corti-
costeroids, and other progesterone metabolites [19].
Levels of 5aPR are upregulated by 5aP itself and estra-
diol, and downregulated by 3aHP in both ER/PR-posi-
tive and -negative cells [29]. The mechanisms of action
resulting in the opposing effects of these two hormones





Figure 5 Examples of MDA-MB-231 tumors and tumor histology from 5aP- and 3aHP-treated mice. (A) Large aggressive tumor from a
5aP-treated mouse, with histologic sections showing (B) invasion of rib-cage muscle by the spreading tumor cells, and (C) higher magnification
of region with numerous mitoses (arrows). (D) Residual tumor from a 3aHP-treated mouse, with no signs of invasion (E) and showing region of
tumor with numerous apoptotic and necrotic cells (F). Formalin-fixed sections (5 μm) stained with hematoxylin and eosin. Scale bars at 1.0 cm
for whole tumors (A, D), at 160 µm for (B) and (E), and at 40 µm for (C) and (F).
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the plasma membrane receptors, as well as altered gene
expression. Indications are that 5aP acts via the surface
receptor-linked mitogen-activated protein kinase (MAPK;
Erk1/2) pathway; 5aP significantly stimulates activation of
Erk1/2 [30], increases the Bcl-2/Bax expression ratio [18]
and actin depolymerization [31], and decreases expression
of actin and adhesion plaque-associated vinculin [31],
resulting in decreased apoptosis and increased mitosis and
cell detachment. Conversely, 3aHP appears to suppress
protein kinase C (PKC), phospholipase C (PLC), Ca2+
mobilization (unpublished observations), and the Bcl-2/
Bax expression ratio [18], and increases expression of the
cell-cycle inhibitor p21 [18], resulting in increased apopto-
sis and decreased proliferation and detachment of breast
cell lines. In pituitary cells, 3aHP also has been shown to
inhibit a plasma membrane-associated PKC, PLC, Ca2+
cell-signaling pathway [32].
The results of the studies reported here not only show
that 5aP and 3aHP have opposing effects on initiation
and growth of ER/PR-negative human breast tumors,
but also provide in vivo evidence of the marked changes
in the relative concentrations of these hormones in the
tumor microenvironment. Whereas serum from control
mice, in which implanted human breast cells had not
developed into tumors, contained about equal concen-
trations of 5aP and 3aHP, serum from mice with
tumors had significantly more 5aP than 3aHP. Because
hormones had not been administered to these mice, the
higher 5aP/3aHP ratio in serum from tumor-bearing
mice can reasonably be expected to have resulted from
the tumors, which on average had about threefold
higher concentrations of 5aP than the respective sera,
and >10-fold higher 5aP than 3aHP levels. Previous in
vitro metabolism studies showed that human breast
tumor tissues convert significantly more progesterone to
5a-pregnanes like 5aP and less to 4-pregnenes like
3aHP than do paired normal (nontumorous) tissues
[15] and that these differences correlated with signifi-
cantly higher 5a-reductase gene (SRD5A1, SRD5A2) and
lower 3a(20a)-HSO gene (AKR1C1, AKR1C2, AKR1C3)
expression in tumor tissues [33]. Similar differences in
progesterone metabolism and enzyme gene expressions
were observed between tumorigenic and nontumorigenic
breast cell lines [16]. In addition to the ability to convert
progesterone to active cancer-regulating hormones,
breast carcinomas are able to synthesize progesterone
[34,35], which could account for its relatively high con-
centrations in the xenograft tumors reported here, and
indicate an in situ supply of the biosynthetic precursor
of 5aP and 3aHP.
The significant concentrations of 5aP and 3aHP, and
particularly the high 5aP/3aHP ratios, in the MDA-MB-
231 xenograft tumors, emphasize the potential importance
of the microenvironment within breast tissue where the
biologic actions occur. The role of the microenvironment
in changing the expression of regulatory factors such as
metabolizing enzymes, receptors, cytoskeletal and adhe-
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Figure 6 Hormone levels in serum. (A) Serum hormone levels after treatment. Serum samples (n = 4 to 5) were analyzed 15 to 22 days and
42 days after mice received an injection of vehicle (control), 5aP, or 3aHP. Data points represent nanograms per milliliter (mean ± SEM). (**P <
0.01 compared with respective controls). (B) Hormone levels in serum from 10 control (vehicle only) mice, six of which had developed tumors
spontaneously (With tumor), and four that remained without tumors (No tumor). Hormone levels were determined with RIA and are presented
as nanograms per milliliter 5aP, 3aHP, and progesterone (Pro) and (C) as the ratio of 5aP to 3aHP. *P < 0.05; **P < 0.01 for the comparison, as
indicated or versus the levels in the “No tumor” mice.
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epigenetic alterations has been extensively reviewed
[36-40]. The current findings, along with the previous in
vitro studies, suggest that the relative concentrations of
5aP and 3aHP in the breast microenvironment constitute
important autocrine/paracrine determinants not only for
tumorigenesis but also for potential regression of tumors
and the maintenance of normalcy of ER/PR-negative
breast cells/tissues. Figure 8 provides a summary of oppos-
ing biologic actions and proposed mechanisms of action of
the progesterone metabolites, 5aP and 3aHP, in promot-
ing neoplasia and tumorigenesis, as well as in maintaining
normalcy in ER/PR-negative human breast cells. Evidence
presented here shows that a high concentration of 5aP,
relative to 3aHP in the microenvironment, promotes
initiation and growth of tumors, whereas a higher concen-
tration of 3aHP, relative to 5aP, suppresses tumorigenesis
and promotes normalcy. Previous evidence indicates that






































































































Figure 7 Hormone levels in tumors. (A) Effect of hormone treatment on 5aP and 3aHP levels in tumors. Hormone levels in tumors from four
vehicle-injected, five 5aP-treated, and four 3aHP-treated mice were determined with RIA, as described in Methods. Hormone levels are
presented as nanograms per milliliter 5aP and 3aHP and (B) as the ratio of 5aP to 3aHP. (**P < 0.01 for the comparison between 5aP and
3aHP levels). (C) Levels of 5aP, 3aHP, and progesterone (Pro) in tumors and respective sera from nine mice were determined after extraction
with organic solvents and separation by thin-layer chromatography (TLC) as described in Methods. Levels of hormones are presented as
nanograms per milliliter (serum) and nanograms per milligram (tumors), and (D), as the ratio of 5aP to 3aHP. **, ***Significantly different from
serum levels at P < 0.01 and P < 0.001, respectively.
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via the opposing actions of the hormones on cell prolifera-
tion (mitosis, apoptosis), adhesion, cell cycle, regulatory
and signaling molecules, and gene expression after binding
to specific receptors.
How might higher levels of either 5aP or 3aHP in the
serum due to the steroid implants have, respectively,
initiated/promoted or suppressed xenograft tumorigen-
esis? The 5aP and 3aHP treatments, consisting of
autocrine
R
































Figure 8 Summary of the opposing autocrine/paracrine effects of the progesterone metabolites, 5aP and 3aHP, in a stylized ER/PR-
negative human breast cell. Evidence presented here shows that a high concentration of 5aP relative to 3aHP, in the microenvironment,
promotes initiation and growth of ER/PR-negative human breast cell tumors, whereas a higher concentration of 3aHP, relative to 5aP,
suppresses tumorigenesis and promotes normalcy. Progesterone is converted to 3aHP and 5aP in breast cells. Tumorigenic and tumor cells
convert more progesterone to 5aP and less to 3aHP than do normal cells. The steroids, being lipophylic, are able to pass out of cells and result
in a concentration buildup in the microenvironment. The result is a significant increase in the 5aP-to-3aHP concentration ratio in the
microenvironment of tumorigenic cells and within tumorous tissues in comparison with normal (nontumorous) breasts. 3aHP and 5aP bind to
specific receptors on the plasma membrane linked to signaling pathways involving PKC, phospholipase C, and Ca2+ mobilization (3aHP) and
MAPK/Erk1/2 (5aP) and to modulators of gene expression. The cancer-inhibiting actions of 3aHP result in decreased proliferation and
detachment of cells, increased apoptosis, and suppression of tumor initiation and growth. The cancer-promoting actions of 5aP have the
opposite effects and result in stimulation of tumorigenesis and tumor growth. The evidence suggests that high concentrations of 5aP relative to
3aHP in the microenvironment will promote progression toward neoplasia and tumorigenesis, whereas a low 5aP-to-3aHP concentration ratio
favors maintenance of the normal state.
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suspensions placed subcutaneously in the nape of the
neck, resulted in elevated serum levels of either hor-
mone, which persisted for about 2 to 3 weeks after the
last injection. Because the depots were not far removed
from the site of the cell implants, lymph drainage may
have resulted in significantly higher concentrations of
each applied hormone in the immediate vicinity of the
implanted human cells. Conceivably, in the 5aP-treated
mice, the induced elevation of 5aP levels, relative to
3aHP, in the microenvironment of the human cell
implants, could have exerted procancer actions that
initiated tumorigenesis. Because 5a-reductase and 5aPR
levels are upregulated by 5aP [29], the in situ produc-
tion and paracrine/autocrine actions of locally elevated
5aP could then have autoenhanced hormone-receptor
interaction and the resulting stimulation of tumor
growth, as illustrated in Figure 8. In a like manner, in
the 3aHP-treated mice, the elevated 3aHP levels, rela-
tive to 5aP, in the microenvironment could have
opposed progression to xenograft neoplasia by its inher-
ent anticancer actions and the suppression of 5aP
synthesis and 5aPR expression [29]. By extension, in an
intact human breast, local changes in relative concentra-
tions of 5aP and 3aHP (that is, changes in the 5aP/
3aHP ratio) resulting from selective up- or downregula-
tion of progesterone-metabolizing enzymes induced by
microenvironmental triggers could determine ER/PR-
negative breast cell progression to tumor initiation and
growth or maintenance of normalcy. Because only small
changes in enzyme activity/expression are needed to
result in significant local concentration changes, either a
slight elevation of 5a-reductase, or a reduction of 3a-
HSO, in one or more cells could lead to an increase in
the ratio of 5aP/3aHP in the immediate intra- and
extracellular environment. Conversely, processes that
result in higher levels of cancer-suppressing 3aHP (and
consequently lower 5aP/3aHP ratios) could ensure
maintenance of normalcy.
Because in vitro studies have shown that both ER- and/
or PR-negative and -positive breast cells respond in a sti-
mulatory and inhibitory fashion, respectively, to 5aP and
3aHP, and have 5aPR and 3aHPR, the present results
also may have implications for the substantial numbers
(20% to 40%) of ER/PR-positive patients who fail to
respond to suppression of estrogen and/or progesterone
levels or actions [4,41,42], as well as for those receptor-
positive tumors that do respond to hormonal therapies.
In this regard, the opposing actions of the progesterone
metabolites also appear to exert some control over the
estrogen-regulated effects on breast cancer by their abil-
ity to modulate ER numbers in ER-positive cells [43].
Furthermore, because both tumorigenic and normal
(nontumorigenic) breast cells respond to the opposing
actions of 5aP and 3aHP, the relative concentrations of
the progesterone metabolites in the microenvironment
may also play a role in maintaining normalcy of breast
tissues in general, regardless of ER/PR status.
Conclusions
In vivo evidence shows that the progesterone metabo-
lites, 5aP and 3aHP, control tumorigenesis of ER/PR-
negative human breast cells: 5aP stimulates, whereas
3aHP suppresses, initiation and growth of tumors.
Although both hormones can be synthesized by breast
cells/tissues, tumors produce significantly more 5aP
than 3aHP, resulting in high 5aP/3aHP ratios in the
breast microenvironment. The findings provide the first
hormonal explanation of the regulation of ER/PR-nega-
tive breast tumors. The results suggest new hormonal
biomarkers, diagnostics, and therapeutics for these
aggressive “receptor-negative” breast tumors that are
unresponsive to current hormonal therapies. Moreover,
because both ER/PR-negative and ER/PR-positive, as
well as normal and tumorigenic human breast cell lines,
have been shown to respond to 5aP and 3aHP in vitro,
it is suggested that these endogenously produced pro-
gesterone metabolites may also play regulatory hormo-
nal roles in ER/PR-positive breast cancers, as well as in
the maintenance of normalcy in nontumorous breast tis-
sues. The in vivo data provide further evidence that pro-
gesterone metabolites, such as 5aP and 3aHP, deserve
to be considered as active hormones in their own right,
rather than inactive waste products, and that they must
be considered in the development of new approaches to
prevention, detection, and treatment of breast cancers.
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Additional file 1: Mass spectrometry (GC-MS) of 3aHP, 5aP, and
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radioimmunoassay (RIA) and GC-MS.
Additional File 3: Additional experiment showing the opposing
effects of 5aP and 3aHP on ER/PR-negative breast cell
tumorigenesis and growth. (Similar to Figure 3).
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